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BACKGROUND
Serelaxin is a recombinant form of human relaxin-2, a vasodilator hormone that con-
tributes to cardiovascular and renal adaptations during pregnancy. Previous studies 
have suggested that treatment with serelaxin may result in relief of symptoms and in 
better outcomes in patients with acute heart failure.
METHODS
In this multicenter, double-blind, placebo-controlled, event-driven trial, we enrolled 
patients who were hospitalized for acute heart failure and had dyspnea, vascular con-
gestion on chest radiography, increased plasma concentrations of natriuretic peptides, 
mild-to-moderate renal insufficiency, and a systolic blood pressure of at least 125 mm Hg, 
and we randomly assigned them within 16 hours after presentation to receive either a 
48-hour intravenous infusion of serelaxin (30 μg per kilogram of body weight per day) 
or placebo, in addition to standard care. The two primary end points were death from 
cardiovascular causes at 180 days and worsening heart failure at 5 days.
RESULTS
A total of 6545 patients were included in the intention-to-treat analysis. At day 180, 
death from cardiovascular causes had occurred in 285 of the 3274 patients (8.7%) in 
the serelaxin group and in 290 of the 3271 patients (8.9%) in the placebo group (haz-
ard ratio, 0.98; 95% confidence interval [CI], 0.83 to 1.15; P = 0.77). At day 5, worsening 
heart failure had occurred in 227 patients (6.9%) in the serelaxin group and in 252 
(7.7%) in the placebo group (hazard ratio, 0.89; 95% CI, 0.75 to 1.07; P = 0.19). There 
were no significant differences between the groups in the incidence of death from any 
cause at 180 days, the incidence of death from cardiovascular causes or rehospitaliza-
tion for heart failure or renal failure at 180 days, or the length of the index hospital 
stay. The incidence of adverse events was similar in the two groups.
CONCLUSIONS
In this trial involving patients who were hospitalized for acute heart failure, an infu-
sion of serelaxin did not result in a lower incidence of death from cardiovascular causes 
at 180 days or worsening heart failure at 5 days than placebo. (Funded by Novartis 
Pharma; RELAX-AHF-2 ClinicalTrials.gov number, NCT01870778.)
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Acute heart failure remains a lead-ing cause of hospitalization. Among hos-pitalized patients with acute heart failure, 
10 to 15% have worsening heart failure during 
the hospitalization,1-6 and 10 to 15% die within 
60 to 90 days after discharge7; these numbers are 
dramatically higher than those among patients 
with stable chronic heart failure.8-11 The risk of 
death among hospitalized patients remains 5 to 
10 times as great, even months after the initial 
episode, as the risk among patients who had not 
been hospitalized, which suggests that conges-
tion and end-organ damage caused by decompen-
sation may accelerate the rate of disease pro-
gression and increase the risk of death.12,13
The hormone relaxin contributes to many of 
the changes in cardiovascular and renal function 
observed during pregnancy14,15 and has vasodila-
tory, antifibrotic, and antiinflammatory effects 
and protective effects on end organs.14 Serelaxin, 
a recombinant form of human relaxin-2, was de-
veloped as a potentially useful therapeutic agent 
because of both its vasodilatory effects (to re-
lieve congestion) and its direct protective effects 
on organs. In the Relaxin in Acute Heart Failure 
(RELAX-AHF) trial, administration of serelaxin 
resulted in a lower incidence of worsening heart 
failure during hospitalization and, in an explor-
atory analysis, lower cardiovascular mortality at 
180 days than placebo.16 However, the RELAX-AHF 
trial was not designed to show an effect on mortal-
ity. The second RELAX-AHF trial (RELAX-AHF-2) 
was designed to test the hypothesis that early 
administration of serelaxin in patients admitted 
for acute heart failure could result in lower car-
diovascular mortality at 180 days and a lower 
incidence of worsening heart failure in the first 
5 days than placebo.17
Me thods
Trial Design and Oversight
RELAX-AHF-2 was a multicenter, randomized, 
double-blind, placebo-controlled, event-driven trial 
of serelaxin in addition to standard care in pa-
tients with acute heart failure. The trial design 
has been published previously,17 and the protocol 
and statistical analysis plan are available with 
the full text of this article at NEJM.org. The 
ethics committee at each trial center approved the 
trial, and all patients provided written informed 
consent.
The executive committee, in collaboration with 
the sponsor (Novartis Pharma), developed and 
amended the protocol and oversaw the execution 
of the trial (see the Supplementary Appendix, 
available at NEJM.org, for listings of committee 
members and investigators and the role of the 
sponsor). An independent clinical-events com-
mittee, whose members were unaware of the 
group assignments, adjudicated all deaths and 
hospitalizations that occurred up to and includ-
ing day 180. The independent data monitoring 
committee, supported by an autonomous statis-
tical center that had access to unblinded data, 
regularly reviewed safety data and also reviewed 
the results of the interim efficacy analysis. The 
data were analyzed by the sponsor with verifica-
tion by statisticians at an independent statistical 
center. The authors had access to the data and 
vouch for the completeness and accuracy of the 
data and analyses and for the fidelity of the trial 
to the protocol.
Trial Population
Male and female patients (≥18 years of age) were 
eligible for enrollment in the trial if they were 
admitted to the hospital for acute heart failure with 
dyspnea, congestion on chest radiography, elevat-
ed plasma concentrations of brain natriuretic pep-
tide or N-terminal pro–brain natriuretic peptide, 
a systolic blood pressure of at least 125 mm Hg, 
and mild-to-moderate renal impairment (defined 
as an estimated glomerular filtration rate of 25 to 
75 ml per minute per 1.73 m2 of body-surface 
area), and if they were expected to receive intra-
venous therapy for at least 48 hours. Eligible pa-
tients had to be symptomatic after initial treat-
ment with at least 40 mg of furosemide or 
equivalent, administered intravenously, and had 
to undergo randomization within 16 hours after 
either presentation to the hospital or the first 
intravenous administration of a loop diuretic. 
Patients who received intravenous nitrates at a 
dose of 0.1 mg or less per kilogram of body 
weight per hour were eligible if the systolic blood 
pressure was more than 150 mm Hg. A full list 
of eligibility criteria was published previously and 
is provided in the Supplementary Appendix.17
Procedures
Patients were randomly assigned, in a 1:1 ratio 
with the use of an interactive voice-recognition 
system, to receive an intravenous infusion of either 
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serelaxin (at a dose of 30 μg per kilogram per 
day, adjusted according to weight) or matching 
placebo, beginning no more than 4 hours after 
randomization and continuing for up to 48 hours 
(Table S1 in the Supplementary Appendix). If the 
systolic blood pressure decreased by more than 
40 mm Hg from baseline and the absolute value 
was 100 mm Hg or more in two consecutive 
measurements 15 minutes apart, the infusion 
rate was decreased by 50% (as detailed in the 
protocol). If the systolic blood pressure was below 
100 mm Hg in two consecutive measurements 
15 minutes apart, the infusion was permanently 
discontinued. Investigators were encouraged to 
offer guideline-recommended therapy through-
out the course of the trial. After randomization, 
the investigator could prescribe any additional 
appropriate medications.
Patients were assessed daily for the first 5 days 
or until discharge and on days 14, 60, 120 (the 
assessment on day 120 was performed by tele-
phone), and 180. Signs and symptoms of heart 
failure were assessed until day 60, and hemato-
logic and clinical chemical variables were as-
sessed locally until day 5. Adverse events were 
reported from the time the patient gave informed 
consent until day 5 for nonserious events and 
until day 14 for serious events.
Primary and Secondary End Points
The trial had two primary efficacy end points: 
death from cardiovascular causes at 180 days 
and worsening heart failure at 5 days. The trial 
was initially designed with a single primary 
end point (death from cardiovascular causes at 
180 days). Worsening heart failure at 5 days was 
changed from a secondary end point to a pri-
mary end point in protocol amendment 5, which 
was finalized on February 18, 2015, after 3140 
patients of the total 6600 had undergone random-
ization.17 Worsening heart failure was defined as 
worsening signs or symptoms of heart failure 
that led to an intensification of treatment for 
heart failure. Such treatment was defined as 
initiation or increased dose of intravenous ther-
apy with a diuretic, nitrate, or other medication 
for heart failure or institution of mechanical sup-
port such as mechanical ventilation, ultrafiltra-
tion, hemodialysis, an intraaortic balloon pump, 
or a ventricular-assist device. The end point of 
worsening heart failure also included death 
from any cause or rehospitalization for heart 
failure among patients who had been discharged 
before day 5.
Secondary efficacy end points included death 
from any cause at 180 days, the length of the 
index hospital stay, and death from cardiovascu-
lar causes or rehospitalization for heart failure or 
renal failure at 180 days. Rehospitalization was 
defined as an unplanned admission to a hospital 
or a stay in an acute care facility of at least 24 
hours.
Statistical Analysis
RELAX-AHF-2 was an event-driven trial. After ac-
counting for one interim analysis, we determined 
that 547 confirmed cardiovascular deaths would 
be needed to give the trial 80% power to detect 
a 22% lower relative risk of death from cardio-
vascular causes in the serelaxin group than in 
the placebo group. Assuming that 9% of patients 
in the placebo group would die by day 180 (as 
observed in the RELAX-AHF trial13), we calculated 
that approximately 6800 patients would need to 
be enrolled. With the use of a multiple-testing 
procedure, we determined that the sample size 
of 6800 patients would give the trial 80% power 
to detect a 20% lower relative risk of worsening 
heart failure in the serelaxin group than in the 
placebo group, assuming that 12.2% of patients 
in the placebo group would have worsening 
heart failure (on the basis of results from the 
RELAX-AHF trial).
An interim efficacy analysis of cardiovascular 
death was planned after at least 60% (or 329) of 
the planned total confirmed deaths from cardio-
vascular causes had occurred. A Lan–DeMets 
spending function approximating an O’Brien–
Fleming stopping boundary was used to control 
the overall two-sided alpha level at 4% for the 
end point of death from cardiovascular causes 
(adjusted P = 0.0384). The results of the interim 
analysis did not cross the stopping boundary 
(details are provided in the Supplementary Ap-
pendix).
Primary and secondary efficacy end points, 
with the exception of death from any cause, were 
compared between groups on an intention-to-
treat basis with the use of a sequentially rejective 
multiple-testing procedure18 to control the over-
all two-sided alpha level at 5% (with adjustment 
for the interim analysis). At 180 days, the time 
to cardiovascular death was compared between 
groups with a log-rank test, with four fifths of 
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the alpha assigned to that end point (final ad-
justed P = 0.0372). The time to worsening heart 
failure through day 5 was compared between 
groups with the use of Gehan’s generalized Wil-
coxon test, with one fifth of the alpha assigned 
to that end point (final adjusted P = 0.0094). If the 
test of either or both of the primary end points 
was significant, death from any cause would be 
tested independently at the two-sided 5% signifi-
cance level.
R esult s
Patients
From October 2, 2013, to February 1, 2017, a 
total of 7554 patients at 546 centers in 35 coun-
tries were screened. Of these patients, 954 did 
not meet the criteria for randomization (the 
most frequent reasons are listed in Table S2 in 
the Supplementary Appendix). A total of 6600 
patients underwent randomization: 3298 were 
assigned to the serelaxin group, and 3302 to the 
placebo group. A total of 55 patients underwent 
randomization in error and did not take the trial 
drug or were enrolled at a site that was closed 
because of Good Clinical Practice violations and 
were therefore prospectively omitted from all 
analyses before the end of the trial. Accordingly, 
3274 patients assigned to receive serelaxin and 
3271 assigned to receive placebo were included 
in the intention-to-treat analysis (Fig. S1 in the 
Supplementary Appendix). The groups were bal-
anced with respect to baseline characteristics 
(Table 1, and Table S3 in the Supplementary Ap-
pendix).
Trial Intervention and Follow-up
Patients underwent randomization a median of 
5.3 hours after the first intravenously adminis-
tered dose of a loop diuretic, and serelaxin or 
placebo was initiated a median of 0.5 hours after 
randomization. The median duration of infusion 
was 48.0 hours in both groups. A total of 40 
patients in the serelaxin group and 55 patients 
in the placebo group did not receive the infusion. 
The mean blood pressure was lower among pa-
tients in the serelaxin group than among those 
in the placebo group after 30 minutes of infu-
sion and remained lower for 3 days (Fig. 1, and 
Table S4 in the Supplementary Appendix).
Infusions were permanently discontinued in 
717 patients (21.9%) in the serelaxin group and 
in 512 patients (15.7%) in the placebo group 
(Tables S5 and S6 in the Supplementary Appen-
dix). The most common reason for discontinua-
tion was a decrease in systolic blood pressure 
that met the criteria for discontinuation in accor-
dance with the protocol (18.5% of patients in the 
serelaxin group and 12.5% in the placebo group); 
in addition, 1.3% of patients in the serelaxin 
group and 1.4% in the placebo group prema-
turely discontinued infusions because of adverse 
events. Concomitant medications during the trial 
are shown in Tables S7 through S9, and the 
number of patients who received diuretics intra-
venously and the mean dose per patient are 
shown in Table S10, in the Supplementary Ap-
pendix.
Patients in the serelaxin group were followed 
for a mean (±SD) of 167.6±38.2 days, and pa-
tients in the placebo group for 166.5±40.0 days. 
Vital status at the end of follow-up was un-
known for 16 patients (8 patients in each group 
[0.2%]), and 2 patients in the placebo group 
were lost to follow-up.
Primary and Key Secondary End Points
At day 180, adjudicated death from cardiovascu-
lar causes (one of the two primary end points) 
had occurred in 285 patients (8.7%) in the sere-
laxin group and in 290 (8.9%) in the placebo 
group (hazard ratio, 0.98; 95% confidence inter-
val [CI], 0.83 to 1.15; P = 0.77). At day 5, worsen-
ing heart failure (the other primary end point) 
had occurred in 227 patients (6.9%) in the sere-
laxin group and in 252 (7.7%) in the placebo 
group (hazard ratio, 0.89; 95% CI, 0.75 to 1.07; 
P = 0.19) (Table 2 and Fig. 2A and 2B). Analysis 
of both primary end points in the per-protocol 
population showed similar results (Table S11 in 
the Supplementary Appendix). Subgroup analy-
ses of both primary end points are shown in 
Figure S2 in the Supplementary Appendix.
In accordance with the multiple-testing pro-
cedure, the key secondary end points were not 
tested for significance; hazard ratios and unad-
justed 95% confidence intervals are shown in 
Table 2. At 180 days, the incidence of death from 
any cause was similar in the serelaxin group and 
the placebo group (11.2% and 11.9%, respective-
ly), as was the incidence of death from cardio-
vascular causes or rehospitalization for heart 
failure or renal failure (24.3% and 24.9%, respec-
tively) (Fig. 2C, and Fig. S3 in the Supplementary 
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Characteristic
Serelaxin Group 
(N = 3274)
Placebo Group 
(N = 3271)
Age — yr 73.1±11.2 72.8±11.2
Age group — no. (%)
<75 yr 1608 (49.1) 1635 (50.0)
≥75 yr 1666 (50.9) 1636 (50.0)
Male sex — no. (%) 1978 (60.4) 1930 (59.0)
Race — no. (%)†
White 3017 (92.2) 2999 (91.7)
Black 163 (5.0) 171 (5.2)
Other or missing data 94 (2.9) 101 (3.1)
Weight — kg 84.0±20.0 84.3±20.2
Body-mass index‡ 29.8±6.4 29.8±6.3
Systolic blood pressure — mm Hg 146.3±16.9 146.1±16.5
Diastolic blood pressure — mm Hg 82.2±14.2 82.0±13.9
Heart rate — beats/min 83.5±17.0 83.5±17.1
Respiratory rate — breaths/min 22.0±4.6 21.9±4.6
Temperature — °C 36.5±0.4 36.5±0.4
History of heart failure — no./total no. (%) 2411/3272 (73.7) 2443/3269 (74.7)
Previous hospitalization for heart failure — no./total no. (%) 1647/3066 (53.7) 1691/3049 (55.5)
No. of hospitalizations for heart failure within previous 1 yr 1.1±1.2 1.2±1.2
Ischemic cause of heart failure — no./total no. (%) 1313/2409 (54.5) 1294/2438 (53.1)
Ejection fraction at index hospitalization — %§ 39.3±13.9 38.5±13.7
Ejection fraction ≤40% — no./total no. (%) 1571/3074 (51.1) 1609/3054 (52.7)
NYHA class 1 mo before admission — no./total no. (%)
I 116/2365 (4.9) 94/2384 (3.9)
II 914/2365 (38.6) 934/2384 (39.2)
III 1089/2365 (46.0) 1095/2384 (45.9)
IV 246/2365 (10.4) 261/2384 (10.9)
Intravenous nitrates at randomization — no. (%) 179 (5.5) 181 (5.5)
Median BNP level (IQR) — ng/liter¶ 1095 (741–1715) 1200 (773–1992)
Median NT-proBNP level (IQR) — ng/liter‖ 6153 (3613–10,387) 6035 (3485–9567)
eGFR — ml/min/1.73 m2** 51.3±14.3 51.3±14.5
Median time from either presentation or first intravenous loop  
diuretic, whichever occurred earlier, to randomization 
(IQR) — hr
7.1 (4.9–11.1) 6.9 (4.9–11.0)
Median time from presentation to randomization (IQR) — hr 7.0 (4.9–11.0) 6.9 (4.9–10.9)
Median time from first intravenous loop diuretic to randomization 
(IQR) — hr
5.3 (3.1–9.5) 5.2 (3.1–9.3)
Median time from randomization to administration of serelaxin or 
placebo (IQR) — hr
0.5 (0.3–1.0) 0.5 (0.3–1.0)
*  Plus–minus values are means ±SD. There were no significant between-group differences in the listed characteristics 
(P<0.05). Additional baseline characteristics are shown in Table S4 in the Supplementary Appendix. Percentages may 
not total 100 because of rounding. BNP denotes brain natriuretic peptide, IQR interquartile range, NT N-terminal, 
and NYHA New York Heart Association.
†  Race was reported by the patient.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  Data were available for 3074 patients in the serelaxin group and 3054 patients in the placebo group.
¶  Data were available for 654 patients in the serelaxin group and 652 patients in the placebo group.
‖  Data were available for 2631 patients in the serelaxin group and 2630 patients in the placebo group.
**  Estimated glomerular filtration rate (eGFR) was calculated with the use of the simplified Modification of Diet in Renal 
Disease formula, which takes into account age, sex, race, and serum creatinine level.19
Table 1. Selected Characteristics of the Patients in the Intention-to-Treat Population at Baseline.*
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Appendix). The median length of stay during the 
index hospitalization was also similar in the two 
groups (6.8 days in the serelaxin group and 6.9 
days in the placebo group).
Safety
A similar percentage of patients in each group 
had at least one adverse event in the first 5 days 
(53.1% in the serelaxin group and 52.1% in the 
placebo group) (Table 3). Adverse events and 
serious adverse events that occurred up to and 
including day 14 were also similar in the two 
groups; 55.3% in the serelaxin group and 54.5% 
in the placebo group had an adverse event, and 
12.6% and 13.1%, respectively, had a serious ad-
verse event. Additional information about adverse 
events and laboratory data that were collected 
for safety analyses are provided in Tables S12 
through S14 in the Supplementary Appendix.
Discussion
In the RELAX-AHF-2 trial, a 48-hour infusion of 
serelaxin in patients with acute heart failure did 
not result in a lower incidence of death from 
cardiovascular causes at 180 days or worsening 
heart failure at 5 days than placebo. In addition, 
serelaxin was not associated with a shorter length 
of index hospital stay or a lower incidence of 
rehospitalization for heart failure or renal failure 
than placebo. Administration of serelaxin result-
ed in a greater reduction in blood pressure than 
did placebo, which is consistent with a pharma-
cologic effect.
The RELAX-AHF-2 trial was prospectively 
powered to evaluate the effect of serelaxin on 
death from cardiovascular causes at 180 days. 
However, it did not replicate the benefit of sere-
laxin with respect to cardiovascular mortality 
Figure 1. Systolic Blood Pressure through 120 Hours According to Group.
Asterisks indicate time points at which the between-group difference was 
significant (P<0.05) (see also Table S4 in the Supplementary Appendix).  
I bars indicate standard errors.
M
ea
n 
Sy
st
ol
ic
 B
lo
od
 P
re
ss
ur
e
(m
m
 H
g)
145
135
140
130
125
120
0
0 6 2412 48 72 96 120
Hours
Placebo
Serelaxin
*
* *
* *
End Point
Serelaxin Group 
(N = 3274)
Placebo Group 
(N = 3271)
Hazard Ratio or Mean 
Difference (95% CI)* P Value
Primary efficacy end points — no. (%)
Death from cardiovascular causes at 180 days 285 (8.7) 290 (8.9) 0.98 (0.83 to 1.15) 0.77†
Worsening heart failure at 5 days 227 (6.9) 252 (7.7) 0.89 (0.75 to 1.07) 0.19‡
Key secondary efficacy end points
Death from any cause at 180 days — no. (%) 367 (11.2) 388 (11.9) 0.94 (0.81 to 1.08)
Median length of index hospital stay (IQR) — days§ 6.8 (5.0 to 10.0) 6.9 (5.0 to 10.0) −0.183 (−0.645 to 0.280)¶
Composite of death from cardiovascular causes or 
rehospitalization for heart failure or renal 
failure at 180 days — no. (%)
794 (24.3) 813 (24.9) 0.97 (0.88 to 1.07)
Death from cardiovascular causes 285 (8.7) 290 (8.9) 0.98 (0.83 to 1.15)
Rehospitalization for heart failure or renal failure 604 (18.4) 632 (19.3) 0.95 (0.85 to 1.06)
*  The 95% confidence intervals have not been adjusted for multiple comparisons, and therefore inferences drawn from these intervals may 
not be reproducible.
†  The P value was calculated with the use of the log-rank test.
‡  The P value was calculated with the use of Gehan’s generalized Wilcoxon test.
§  The length of stay for patients who were still in the hospital on day 60 was truncated at 60 days, and the value for patients who died in the 
hospital was imputed as 61 days.
¶  The value is the mean difference between the groups; the 95% confidence interval was calculated with the use of the bootstrap method.
Table 2. Protocol-Specified Efficacy End Points.
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that was seen in the previous RELAX-AHF trial.16 
One explanation for these disparate results is 
that the result in the RELAX-AHF trial was due 
to chance. The P value for the between-group 
comparison of death from cardiovascular causes 
(an exploratory outcome) in the RELAX-AHF trial 
was 0.028, without correction for multiple test-
ing. The RELAX-AHF-2 trial was specifically de-
signed to determine whether this result could be 
confirmed; therefore, death from cardiovascular 
causes was a primary end point. The RELAX-AHF-2 
trial was also more than five times larger than 
the previous trial. The negative result for the end 
point of death from cardiovascular causes in the 
RELAX-AHF-2 trial is therefore consistent with 
the conclusion that the result in the RELAX-AHF 
trial was a chance finding. Other trials of intra-
venous vasodilator therapy during hospitaliza-
tion for acute heart failure (such as ularitide in 
TRUE-AHF [Trial of Ularitide Efficacy and Safe-
ty in Acute Heart Failure]20 and nesiritide in 
ASCEND-HF [Acute Study of Clinical Effectiveness 
of Nesiritide in Decompensated Heart Failure]21) 
have also failed to show a benefit with respect to 
postdischarge cardiovascular mortality. Although 
these previous trials evaluated the administra-
tion of natriuretic peptides, which have a differ-
ent mechanism of action than serelaxin, the re-
sults suggest that short-term interventions in 
patients with acute heart failure may not influence 
long-term outcomes.
However, differences in patient characteristics 
between the two RELAX-AHF trials might also 
have been responsible for the different results. 
The entry criteria in the RELAX-AHF-2 trial were 
nearly identical to those in the RELAX-AHF trial, 
but patients with worse renal function could be 
enrolled in the current trial, and there was a 
higher threshold for natriuretic peptides. These 
differences should have resulted in higher car-
diovascular mortality among enrolled patients. 
Yet, death from cardiovascular causes occurred 
in 9.6% (95% CI, 7.5 to 12.3) of patients in the 
placebo group in the RELAX-AHF trial and in 
8.9% (95% CI, 8.1 to 10.5) in the placebo group 
in the RELAX-AHF-2 trial. In contrast, the rate 
of death from noncardiovascular causes was 
higher in this trial than in the RELAX-AHF trial 
(3.0% vs. 1.7%). Thus, potential differences in 
the patient populations and their risk profiles 
may have contributed to the different outcomes 
of the two trials.
The repeated failure of short-term interven-
tions to improve outcomes in acute heart failure 
has focused attention on aspects of clinical trial 
design.22 The timing of therapy, the imprecision 
of the diagnosis of acute heart failure, and the 
failure to align the mechanism of action of the 
drug being evaluated with the patient population 
that is most likely to benefit from it have been 
identified as potential problems. Some studies 
have suggested that earlier treatment of patients 
may result in greater relief of symptoms.23 How-
ever, no difference in treatment effect according 
to the time to randomization was observed in 
either the RELAX-AHF trial or ASCEND-HF.24,25
In-hospital worsening heart failure appears to 
be a clinically meaningful event associated with 
adverse outcomes.26 Its clinical importance has 
been shown in retrospective analyses of patient 
databases and intervention trials.4,6,26-30 In the 
RELAX-AHF trial, serelaxin resulted in 47% fewer 
Figure 2 (facing page). Efficacy End Points.
Panel A shows Kaplan–Meier estimates of the proba-
bility of death from cardiovascular causes. At day 180, 
death from cardiovascular causes had occurred in 285 
patients in the serelaxin group and in 290 patients in 
the placebo group. Panel B shows Kaplan–Meier esti-
mates of the probability of worsening heart failure dur-
ing the first 5 days. At 5 days, worsening heart failure 
had occurred in 227 patients in the serelaxin group and 
in 252 patients in the placebo group. Panel C shows 
Kaplan–Meier estimates of the probability of death from 
any cause. At day 180, death from any cause had occurred 
in 367 patients in the serelaxin group and in 388 patients 
in the placebo group. In each panel, the inset shows the 
same data on an enlarged y axis.
Event
Serelaxin Group 
(N = 3257)
Placebo Group 
(N = 3248) P Value†
no. (%)
Hypokalemia 263 (8.1) 242 (7.5) 0.35
Cardiac failure 192 (5.9) 215 (6.6) 0.23
Muscle spasms 80 (2.5) 49 (1.5) 0.006
Hypotension 77 (2.4) 65 (2.0) 0.32
Headache 74 (2.3) 92 (2.8) 0.15
Constipation 70 (2.1) 57 (1.8) 0.25
Urinary tract infection 63 (1.9) 68 (2.1) 0.65
*  Shown are events that occurred in at least 2% of patients in either group.
†  P values were calculated with the use of the Cochran–Mantel–Haenszel test.
Table 3. Most Frequent Adverse Events up to and Including Day 5.*
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events of worsening heart failure in the first 5 days 
than placebo. In the RELAX-AHF-2 trial, however, 
the lower incidence of worsening heart failure 
in the serelaxin group was not significant. De-
spite the higher plasma concentrations of natri-
uretic peptides at screening among patients in 
the RELAX-AHF-2 trial than among those in the 
RELAX-AHF trial, the percentage of patients 
with worsening heart failure in the placebo group 
was substantially lower in the RELAX-AHF-2 
trial than in the previous trial (7.7% vs. 12.2%). 
Because in the power calculations for the 
 RELAX-AHF-2 trial we assumed that 12.2% of 
patients in the placebo group would have wors-
ening heart failure, this trial had less power than 
anticipated to detect a difference in this end 
point. The percentage of patients in the placebo 
group with worsening heart failure may have been 
lower in the RELAX-AHF-2 trial than in the previ-
ous trial because the patients in the RELAX-AHF-2 
trial may have been at a lower risk for worsening 
heart failure or because of underreporting by in-
vestigators, random variability in the two popula-
tions, or other factors.
Drug-induced hypotension has been a major 
cause of failure in previous trials in acute heart 
failure.5,31 Consequently, the protocol for symp-
tom relief was designed to mitigate the risk of 
clinically significant hypotension by enrolling 
patients with a systolic blood pressure of at least 
125 mm Hg and providing guidelines for dose 
reduction or discontinuation in the event of hy-
potension.32 Approximately 18.5% of patients in 
the serelaxin group discontinued treatment for 
this reason, as compared with 12.5% in the pla-
cebo group. Although this approach effectively 
avoided hypotension-related adverse events, it also 
resulted in a smaller number of patients who 
were treated for a full 48 hours with serelaxin. 
However, no interaction between efficacy and 
the treatment duration was found.
In conclusion, the RELAX-AHF-2 trial evaluat-
ed the effect of serelaxin in patients with acute 
heart failure. Serelaxin treatment resulted in a 
significantly greater reduction in blood pressure 
than placebo, a finding consistent with a pharma-
cologic effect of serelaxin. However, serelaxin 
did not result in lower cardiovascular mortality 
at 180 days or a smaller percentage of patients 
with worsening heart failure at 5 days than pla-
cebo. The incidence of adverse events was simi-
lar in the two groups.
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